Li Qian, Ang Yang, Zhou Qing-Qing, Shi Min, Chen Wei, Wang Yujie, Yu Pan, Wan Bing, Yu Wanyou, Jiang Liping, Shi Yadan, Lin Zhao, Song Shaozheng, Duan Manlin, Long Yun, Wang Qi, Liu Wentao, Bao Hongguang
Department of Anesthesiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210000, China.
Department of Anesthesiology, Jiangning Hospital Affiliated to Nanjing Medical University, Nanjing, 211100, China.
J Pharm Anal. 2025 Mar;15(3):101039. doi: 10.1016/j.jpha.2024.101039. Epub 2024 Jul 18.
Acute respiratory distress syndrome (ARDS) is a common respiratory emergency, but current clinical treatment remains at the level of symptomatic support and there is a lack of effective targeted treatment measures. Our previous study confirmed that inhalation of hydrogen gas can reduce the acute lung injury of ARDS, but the application of hydrogen has flammable and explosive safety concerns. Drinking hydrogen-rich liquid or inhaling hydrogen gas has been shown to play an important role in scavenging reactive oxygen species and maintaining mitochondrial quality control balance, thus improving ARDS in patients and animal models. Coral calcium hydrogenation (CCH) is a new solid molecular hydrogen carrier prepared from coral calcium (CC). Whether and how CCH affects acute lung injury in ARDS remains unstudied. In this study, we observed the therapeutic effect of CCH on lipopolysaccharide (LPS) induced acute lung injury in ARDS mice. The survival rate of mice treated with CCH and hydrogen inhalation was found to be comparable, demonstrating a significant improvement compared to the untreated ARDS model group. CCH treatment significantly reduced pulmonary hemorrhage and edema, and improved pulmonary function and local microcirculation in ARDS mice. CCH promoted mitochondrial peripheral division in the early course of ARDS by activating mitochondrial thioredoxin 2 (Trx2), improved lung mitochondrial dysfunction induced by LPS, and reduced oxidative stress damage. The results indicate that CCH is a highly efficient hydrogen-rich agent that can attenuate acute lung injury of ARDS by improving the mitochondrial function through Trx2 activation.
急性呼吸窘迫综合征（ARDS）是一种常见的呼吸急症，但目前的临床治疗仍停留在对症支持水平，缺乏有效的靶向治疗措施。我们之前的研究证实，吸入氢气可减轻ARDS的急性肺损伤，但氢气的应用存在易燃、易爆的安全隐患。饮用富氢液体或吸入氢气已被证明在清除活性氧和维持线粒体质量控制平衡方面发挥重要作用，从而改善患者和动物模型中的ARDS。珊瑚钙氢化产物（CCH）是一种由珊瑚钙（CC）制备的新型固体分子氢载体。CCH是否以及如何影响ARDS中的急性肺损伤仍未得到研究。在本研究中，我们观察了CCH对脂多糖（LPS）诱导的ARDS小鼠急性肺损伤的治疗效果。发现接受CCH治疗和吸入氢气的小鼠存活率相当，与未治疗的ARDS模型组相比有显著改善。CCH治疗显著减少了ARDS小鼠的肺出血和水肿，改善了肺功能和局部微循环。CCH通过激活线粒体硫氧还蛋白2（Trx2）在ARDS早期促进线粒体周边分裂，改善LPS诱导的肺线粒体功能障碍，并减少氧化应激损伤。结果表明，CCH是一种高效的富氢剂，可通过激活Trx2改善线粒体功能来减轻ARDS的急性肺损伤。
